An essential role for Akt1 in dendritic cell function and tumor immunotherapy

Nature Biotechnology

Volumn 24, Issue 12, 2006, Pages 1581-1590

  Park, Dongsu ^a   Lapteva, Natalia ^b   Seethammagari, Mamatha ^a   Slawin, Kevin M ^b   Spencer, David M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; DRUG THERAPY; IMMUNOLOGY; LIPIDS; POLYSACCHARIDES; VACCINES;

ALLELE ENCODING; DENDRITIC CELL (DC) VACCINES; LIPOPOLYSACCHARIDES; TUMOR IMMUNOTHERAPY;

ONCOLOGY;

CD40 ANTIGEN; DENDRITIC CELL VACCINE; LIPOPOLYSACCHARIDE; PROTEIN BCL 2; PROTEIN KINASE B;

ADJUVANT THERAPY; ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; BONE MARROW CELL; CANCER IMMUNOTHERAPY; CELL FUNCTION; CELL MANIPULATION; CELL MATURATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DENDRITIC CELL; DOWN REGULATION; ENZYME ACTIVATION; ENZYME STABILITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; LIPID RAFT; LYMPHOMA; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; SIGNAL TRANSDUCTION; T LYMPHOCYTE; VACCINATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; APOPTOSIS; BIOSYNTHETIC PATHWAYS; CANCER VACCINES; CARBOXYLIC ESTER HYDROLASES; CELL DIFFERENTIATION; CELL SURVIVAL; DENDRITIC CELLS; DOWN-REGULATION; HUMANS; IMMUNOTHERAPY; LYMPHOMA; MELANOMA; MICE; MICE, KNOCKOUT; MITOCHONDRIAL PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SKIN NEOPLASMS;

MURINAE;

EID: 33845709678     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt1262     Document Type: Article

References (50)

1. Schuler, G., Schuler-Thurner, B. & Steinman, R.M. The use of dendritic cells in cancer immunotherapy. Curr. Opin. Immunol. 15, 138-147 (2003).
2. Ridgway, D. The first 1000 dendritic cell vaccinees. Cancer Invest. 21, 873-886 (2003).
3. Hermans, I.F., Ritchie, D.S., Yang, J., Roberts, J.M. & Ronchese, F. CD8+ T cell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity. J. Immunol. 164, 3095-3101 (2000).
4. Liu, K. et al. Immune tolerance after delivery of dying cells to dendritic cells in situ. J. Exp. Med. 196, 1091-1097 (2002).
5. Park, Y., Lee, S.W. & Sung, Y.C. Cutting Edge: CpG DNA inhibits dendritic cell apoptosis by up-regulating cellular inhibitor of apoptosis proteins through the phosphatidylinositide-3′-OH kinase pathway. J. Immunol. 168, 5-8 (2002).
6. Josien, R. et al. TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo. J. Exp. Med. 191, 495-502 (2000).
7. Miga, A.J. et al. Dendritic cell longevity and T cell persistence is controlled by CD154-CD40 interactions. Eur. J. Immunol. 31, 959-965 (2001).
8. Nopora, A. & Brocker, T. Bcl-2 controls dendritic cell longevity in vivo. J. Immunol. 169, 3006-3014 (2002).
9. Ouaaz, F., Arron, J., Zheng, Y., Choi, Y. & Beg, A.A. Dendritic cell development and survival require distinct NF-kappaB subunits. Immunity 16, 257-270 (2002).
10. Contin, C. et al. Membrane-anchored CD40 is processed by the tumor necrosis factor-alpha-converting enzyme. Implications for CD40 signaling. J. Biol. Chem. 278, 32801-32809 (2003).
11. Hanks, B.A. et al. Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo. Nat. Med. 11, 130-137 (2005).
12. Chuang, T.H. & Ulevitch, R.J. Triad3A, an E3 ubiquitin-protein ligase regulating Toll-like receptors. Nat. Immunol. 5, 495-502 (2004).
13. Wald, D. et al. SIGIRR, a negative regulator of Toll-like receptor-interleukin 1 receptor signaling. Nat. Immunol. 4, 920-927 (2003).
14. Kobayashi, K. et al. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 110, 191-202 (2002).
15. Watanabe, T., Kitani, A., Murray, P.J. & Strober, W. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat. Immunol. 5, 800-808 (2004).
16. Shen, L., Evel-Kabler, K., Strube, R. & Chen, S.Y. Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nat. Biotechnol. 22, 1546-1553 (2004).
17. Mansell, A. et al. Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation. Nat. Immunol. 7, 148-155 (2006).
18. Hou, W.S. & Van Parijs, L.A. Bcl-2-dependent molecular timer regulates the lifespan and immunogenicity of dendritic cells. Nat. Immunol. 5, 583-589 (2004).
19. Brazil, D.P., Yang, Z.Z. & Hemmings, B.A. Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem. Sci. 29, 233-242 (2004).
20. Ishii, K.J. et al. Potential role of phosphatidylinositol 3 kinase, rather than DNA-dependent protein kinase, in CpG DNA-induced immune activation. J. Exp. Med. 196, 269-274 (2002).
21. Ardeshna, K.M., Pizzey, A.R., Devereux, S. & Khwaja, A. The PI3 kinase, p38 SAP kinase, and NF-kappaB signal transduction pathways are involved in the survival and maturation of lipopolysaccharide-stimulated human monocyte-derived dendritic cells. Blood 96, 1039-1046 (2000).
22. Bharti, A.C. & Aggarwal, B.B. Ranking the role of RANK ligand in apoptosis. Apoptosis 9, 677-690 (2004).
23. Yu, Q., Kovacs, C., Yue, F.Y. & Ostrowski, M.A. The role of the p38 mitogen-activated protein kinase, extracellular signal-regulated kinase, and phosphoinositide-3-OH kinase signal transduction pathways in CD40 ligand-induced dendritic cell activation and expansion of virus-specific CD8+ T cell memory responses. J. Immunol. 172, 6047-6056 (2004).
24. Vassiliou, E., Sharma, V., Jing, H., Sheibanie, F. & Ganea, D. Prostaglandin E2 promotes the survival of bone marrow-derived dendritic cells. J. Immunol. 173, 6955-6964 (2004).
25. Kanto, T., Kalinski, P., Hunter, O.C., Lotze, M.T. & Amoscato, A.A. Ceramide mediates tumor-induced dendritic cell apoptosis. J. Immunol. 167, 3773-3784 (2001).
26. Mochizuki, T. et al. Akt protein kinase inhibits non-apoptotic programmed cell death induced by ceramide. J. Biol. Chem. 277, 2790-2797 (2002).
27. Guha, M. et al. Lipopolysaccharide activation of the MEK-ERK1/2 pathway in human monocytic cells mediates tissue factor and tumor necrosis factor alpha expression by inducing Elk-1 phosphorylation and Egr-1 expression. Blood 98, 1429-1439 (2001).
28. Okugawa, S. et al. Janus kinase 2 is involved in lipopolysaccharide- induced activation of macrophages. Am. J. Physiol. Cell Physiol. 285, C399-C408 (2003).
29. Napolitani, G., Bortoletto, N., Racioppi, L., Lanzavecchia, A. & D'Oro, U. Activation of src-family tyrosine kinases by LPS regulates cytokine production in dendritic cells by controlling AP-1 formation. Eur. J. Immunol. 33, 2832-2841 (2003).
30. Woltman, A.M. et al. Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression. Blood 101, 1439-1445 (2003).
31. Granucci, F. et al. Inducible IL-2 production by dendritic cells revealed by global gene expression analysis. Nat. Immunol. 2, 882-888 (2001).
32. Gallucci, S., Lolkema, M. & Matzinger, P. Natural adjuvants: endogenous activators of dendritic cells. Nat. Med. 5, 1249-1255 (1999).
33. Katome, T. et al. Use of RNA interference-mediated gene silencing and adenoviral overexpression to elucidate the roles of AKT/protein kinase B isoforms in insulin actions. J. Biol. Chem. 278, 28312-28323 (2003).
34. Arbibe, L. et al. Toll-like receptor 2-mediated NF-kappa B activation requires a Rac1-dependent pathway. Nat. Immunol. 1, 533-540 (2000).
35. Fujio, Y. & Walsh, K. Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. J. Biol. Chem. 274, 16349-16354 (1999).
36. Mukherjee, A., Arnaud, L. & Cooper, J.A. Lipid-dependent recruitment of neuronal Src to lipid rafts in the brain. J. Biol. Chem. 278, 40806-40814 (2003).
37. Li, B., Desai, S.A., MacCorkle-Chosnek, R.A., Fan, L. & Spencer, D.M. A novel conditional Akt 'survival switch' reversibly protects cells from apoptosis. Gene Ther. 9, 233-244 (2002).
38. Sporri, R. & Reis e Sousa, C. Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function. Nat. Immunol. 6, 163-170 (2005).
39. van Elsas, A. et al. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J. Exp. Med. 194, 481-489 (2001).
40. Napolitani, G., Rinaldi, A., Bertoni, F., Sallusto, F. & Lanzavecchia, A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 6, 769-776 (2005).
41. Jonuleit, H. et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur. J. Immunol. 27, 3135-3142 (1997).
42. Xu, J., Liu, D. & Songyang, Z. The role of Asp-462 in regulating Akt activity. J. Biol. Chem. 277, 35561-35566 (2002).
43. Riesterer, O., Zingg, D., Hummerjohann, J., Bodis, S. & Pruschy, M. Degradation of PKB/Akt protein by inhibition of the VEGF receptor/mTOR pathway in endothelial cells. Oncogene 23, 4624-4635 (2004).
44. Fukao, T. et al. PI3K-mediated negative feedback regulation of IL-12 production in DCs. Nat. Immunol. 3, 875-881 (2002).
45. Martin, M., Rehani, K., Jope, R.S. & Michalek, S.M. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat. Immunol. 6, 777-784 (2005).
46. Del Prete, A. et al. Defective dendritic cell migration and activation of adaptive immunity in PI3Kgamma-deficient mice. EMBO J. 23, 3505-3515 (2004).
47. Beutler, B. & Rietschel, E.T. Innate immune sensing and its roots: the story of endotoxin. Nat. Rev. Immunol. 3, 169-176 (2003).
48. Lutgens, E. et al. Requirement for CD154 in the progression of atherosclerosis. Nat. Med. 5, 1313-1316 (1999).
49. Inaba, K. et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176, 1693-1702 (1992).
50. Nikitina, E.Y. et al. Versatile prostate cancer treatment with inducible caspase and interleukin-12. Cancer Res. 65, 4309-4319 (2005).